- cafead   Apr 17, 2023 at 11:02: PM
via In May of last year, after Seagen rejected Merck’s offer to acquire it for $230 per share, the Seattle biotech saw its value tumble. Just three months later, Merck’s offer had dropped to $195 per share.
But playing the waiting game—and courting another global pharmaceutical powerhouse—worked out favorably for Seagen.
article source
But playing the waiting game—and courting another global pharmaceutical powerhouse—worked out favorably for Seagen.
article source